Evidence map›Paper›PMID 42729211›Full record

ArticleFrontiers in immunology2026

Infections and hypogammaglobulinemia in myasthenia gravis patients receiving low-dose rituximab: a real-world cohort study.

Rongjing Guo, Yifan Zhang, Ting Gao, Zhe Ruan, Chao Sun, Sijia Hao, Yonglan Tang, Qingqing Wang, Xiaoxi Huang, Xiangqi Cao and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Rongjing Guo *Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China.
Yifan Zhang *Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China.
Ting Gao *Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China.
Zhe RuanDepartment of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China.
Chao SunDepartment of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China.
Sijia HaoDepartment of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China.
Yonglan TangDepartment of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China.
Qingqing WangDepartment of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China.
Xiaoxi HuangDepartment of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China.
Xiangqi CaoDepartment of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China.
Zhuyi LiDepartment of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China.
Danni LiuDepartment of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China.
Yu LiuDepartment of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China.
Ting ChangDepartment of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: We investigated the incidence of infections and hypogammaglobulinemia (HGG) in patients with myasthenia gravis (MG) receiving long-term low-dose rituximab (RTX) maintenance therapy and identified related risk factors. Methods: This single-center retrospective cohort study enrolled MG patients treated with low-dose RTX maintenance. Cox proportional hazards regression was performed to analyze risk factors for infections and HGG. Results: A total of 186 patients were included. The median age at RTX initiation was 52.50 years, and the median follow-up was 2.41 years. Infections occurred in 29 patients (15.59%), with a median time to first infection of 170.37 days, mostly during the first cycle. The 1- and 2-year infection rates were 13.41 (95% confidence interval [CI], 8.47-20.28) and 9.20 (95% CI, 6.06-13.36) per 100 person-years. Severe infections developed in 21 patients (11.29%). The most prevalent infection was lower respiratory tract infection (LRTI), with 19 episodes (61.29%). HGG was present in 51 patients (27.42%). HGG was an independent risk factor for infection (HR = 5.53, P<0.001). Higher baseline prednisone dose (HR = 1.25, P = 0.035) and HGG (HR = 7.50, P<0.001) were significantly correlated with increased risk of severe LRTIs. Conclusion: In MG patients receiving long-term low-dose RTX maintenance, the overall infection incidence is relatively low, with LRTIs being the most frequent. HGG is a major independent risk factor for infections and severe LRTIs, while higher baseline prednisone doses were associated with severe LRTIs.

Indexed as

AgammaglobulinemiaImmunologic FactorsInfectionsMyasthenia GravisRituximabAdultAgedFemaleHumansIncidenceMaleMiddle AgedRetrospective StudiesRisk FactorsImmunologic FactorsRituximabhypogammaglobulinemiainfectionmyasthenia gravisprednisonerituximab

Identifiers

PMID42729211
PMCPMC13561787

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.